Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid

Med Pediatr Oncol. 1999 Jun;32(6):457-8. doi: 10.1002/(sici)1096-911x(199906)32:6<457::aid-mpo16>3.0.co;2-n.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticoagulants / adverse effects
  • Anticoagulants / immunology*
  • Bone Marrow Transplantation*
  • Chondroitin Sulfates / immunology*
  • Dermatan Sulfate / immunology*
  • Drug Combinations
  • Enzyme Activation / drug effects
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Heparin / adverse effects
  • Heparinoids / immunology*
  • Heparitin Sulfate / immunology*
  • Hirudin Therapy*
  • Humans
  • Protein C / metabolism*
  • Recombinant Proteins / therapeutic use
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / prevention & control*

Substances

  • Anticoagulants
  • Drug Combinations
  • Fibrinolytic Agents
  • Heparinoids
  • Protein C
  • Recombinant Proteins
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid